One-Stop Preclinical R&D Services for Rare Childhood Diseases
Protheragen is a U.S.-based leader in the field of rare lung disease research, specializing in cutting-edge exploration of pathogenesis, diagnostic markers and therapeutic targets. With in-depth expertise and experience, we provide biopharmaceutical companies of all sizes with one-stop solutions from early diagnosis to therapeutic development, covering key aspects of diagnostic technology development, drug screening and preclinical studies.
Get a Quote
What Are Rare Lung Diseases?
-
Idiopathic Pulmonary Fibrosis (IPF)
IPF is a chronic, progressive, fibrotic interstitial lung disease characterized by scarring of the lungs, resulting in dyspnea, dry cough, and decreased exercise tolerance.
-
Lymphangioleiomyomatosis (LAM)
A rare lung disease that primarily affects the female reproductive system and manifests as cysts in the lungs and pleural effusions that may lead to respiratory failure.
-
Cystic Fibrosis (CF)
A disease that causes thick mucus to build up in the lungs, digestive tract, and other parts of the body.
-
Pulmonary Arterial Hypertension (PAH)
A type of high blood pressure that affects the lungs and the arteries on the right side of the heart.
-
Hypersensitivity Pneumonitis (HP)
An allergic disease that causes inflammation of the small air sacs (alveoli) in the lungs.
-
Pulmonary Alveolar Proteinosis (PAP)
A rare lung disease caused by a buildup of protein, fat, and other substances in the air sacs (alveoli) of the lungs.
Protheragen Leads Innovative Force in Rare Lung Disease Research
Protheragen is a leading international provider of preclinical research services, specializing in a full range of high-quality solutions in the field of rare lung diseases. Our professional services include, but are not limited to, rare lung disease modeling, high-throughput drug screening, biomarker discovery, and comprehensive pharmacokinetic and toxicology studies.
-
Animal Modeling Services for Rare Lung Diseases
-
In Vitro Modeling Services for Rare Lung Diseases
-
Preclinical Pharmacology Studies for Rare Lung Diseases
-
Pharmacokinetic/Pharmacodynamic Studies for Rare Lung Diseases
-
Safety Pharmacology Studies for Rare Lung Diseases
-
Cell and Gene Therapy Development for Rare Lung Diseases
-
Small Molecule Drug Development for Rare Lung Diseases
-
Biomarker Development Services for Rare Lung Diseases
Service Workflow
Prothragen provides experimental services across the early drug discovery and preclinical research process, from early drug discovery, drug to lead compound, lead compound optimization to IND support studies. Working closely with our clients, our multidisciplinary team of experts can provide you with research services tailored to your experimental needs.
-
One-on-one client consultation
-
Preparation of proposals that clearly define project scope, schedule, and cost
-
Experiment execution and data analysis
-
Preparation of final report
Our Featured Platforms
-
Adeno-Associated Viral Vector Development Platform
We have three major AAV technology platforms that simplify the development process of AAV vectors and enhance their functions.
READ MORE
-
Adeno-Associated Viral Vector Development Platform
GeniusAb™: Fully Human Single Domain Antibody Platform
READ MORE
Why Choose Protheragen as a Partner in Rare Lung Disease Research?
-
Rich Experience in Rare Lung Disease Research
We have deep expertise and extensive experience focusing on the pathomechanisms, diagnostic markers and therapeutic targets of rare lung diseases.
-
Comprehensive Research Solutions
We provide a one-stop service covering diagnostic development, drug screening and preclinical studies to accelerate the development of therapies for rare lung diseases.
-
Strong Research Collaboration Network
We maintain close cooperation with the world's top research institutions and pharmaceutical companies, pooling global wisdom to overcome the challenges of rare lung diseases.
-
Efficient Project Management
We offer flexible collaboration models and efficient project management to ensure that projects are completed on time and with high quality.
Frequently Asked Questions (FAQs) About Our Preclinical Research Services
-
How to order specific services from Protheragen?
-
What models are used to study rare lung diseases?
Models commonly used in the study of rare lung diseases include mouse models, rat models, non-human primate models, cell culture models, 3D engineered lung cell models, genetically engineered models, humanized models, and innovative models such as “lobe lung” models. Each of these models has its own advantages and disadvantages, and the choice depends on the objectives of the study and the characteristics of the disease.
-
How are rare lung diseases diagnosed?
Diagnosis of rare lung diseases requires a combination of methods and tools, including clinical presentation, imaging, laboratory testing, pathologic analysis, and multidisciplinary collaboration.
-
How to ensure ethical behavior in preclinical research?
Protheragen adheres to strict ethical guidelines and regulatory standards in all of our research. Our commitment includes obtaining necessary approvals and ensuring humane treatment of animal models.
-
Does Protheragen offer therapeutic services for rare lung diseases?
Protheragen is a preclinical research service provider. We are not a pharmacy or clinic and therefore cannot see patients and do not provide diagnostic and treatment services to individuals.
Leave a Message
Protheragen is a global leader in research solutions for rare lung diseases. We specialize in serving biopharmaceutical companies and research institutions of all sizes, providing comprehensive support from early diagnosis to therapeutic development.